A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
← catalyst calendarNCT06908304 · readout in 346 d
Sponsored by Maia Biotechnology (industry) · MAIA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
300estimated
Sites
15
Countries
Poland, Romania, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-08 | actual | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small -Cell Lung
Interventions
- Drug: 6-Thio-2'-Deoxyguanosine — also filed as 6-thio-dG, THIO, ateganosine
- Drug: Cemiplimab — also filed as LIBTAYO®
- Drug: Docetaxel — also filed as Taxotere, Docecad
- Drug: Vinorelbine — also filed as Navelbine, Vinorelbine tartrate
- Drug: Gemcitabine alone — also filed as Gemzar
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Within 2 Years
Permalink · MAIA's whole pipeline · Catalyst calendar · Every registered study · What changed